In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...
Efficacy and safety of dalpiciclib plus toremifene in advanced HR-positive HER2-negative breast cancer as first-line treatment: A multicenter, single-arm phase II trial. This is an ASCO Meeting ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With ...
First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...
Baseline ctDNA presence linked to larger tumors and higher residual cancer burden scores in HR-positive early breast cancer patients. Persistent ctDNA post-neoadjuvant endocrine therapy associated ...
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a ...
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, ...
(A) The AlphaFold protein structure of GPER from the public database (https://alphafold.com/entry/Q99527). (B) E2, the GPER-specific agonist G1, SERMs, and SERDs ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results